Kamada Stock Sees FY2026 Earnings Estimate Lowered at Sidoti

Key Points

• Sidoti lowered Kamada’s FY2026 earnings estimate to $0.42 per share from $0.46, below the consensus estimate of $0.49; FY2027 EPS is projected at $0.46.
• Analysts remain generally positive, with Kamada holding an average “Buy” rating and a consensus price target of $13.50, including $15.00 targets from UBS and William Blair.
• Kamada’s latest quarterly results exceeded expectations, with $0.16 EPS versus the $0.11 consensus and revenue of $54.92 million; however, its annual dividend was reduced to $0.17 from $0.25.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Stock analysts at Sidoti dropped their FY2026 earnings estimates for shares of Kamada in a research report issued on Friday, September 25th. Sidoti analyst J. Sidoti now anticipates that the biotechnology company will earn $0.42 per share for the year, down from their previous forecast of $0.46. The consensus estimate for Kamada's current full-year earnings is $0.49 per share. Sidoti also issued estimates for Kamada's FY2027 earnings at $0.46 EPS.

A number of other research analysts also recently commented on the company. Wall Street Zen upgraded Kamada from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 15th. William Blair set a $15.00 price target on shares of Kamada in a research report on Tuesday, July 21st. UBS Group reaffirmed a "buy" rating and set a $15.00 price target on shares of Kamada in a research note on Friday, September 18th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Kamada in a research report on Tuesday, September 22nd. Finally, Benchmark reissued a "buy" rating on shares of Kamada in a research note on Tuesday, July 21st. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Kamada has an average rating of "Buy" and an average target price of $13.50.

Kamada Stock Performance

Shares of NASDAQ KMDA opened at $8.62 on Tuesday. The company has a market cap of $495.74 million, a P/E ratio of 22.68, a P/E/G ratio of 0.71 and a beta of 0.88. The firm's fifty day moving average is $7.90 and its two-hundred day moving average is $7.89. Kamada has a 52-week low of $6.50 and a 52-week high of $9.35.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The business had revenue of $54.92 million during the quarter, compared to analyst estimates of $50.84 million.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Kamada stock. Aristides Capital LLC boosted its holdings in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 4.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,491 shares of the biotechnology company's stock after buying an additional 1,476 shares during the quarter. Aristides Capital LLC owned approximately 0.06% of Kamada worth $288,000 as of its most recent SEC filing. Institutional investors own 20.38% of the company's stock.

Kamada Cuts Dividend

The business also recently announced an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were paid a $0.17 dividend. The ex-dividend date was Thursday, August 27th. This represents a yield of 206.0%. This is a decrease from Kamada's previous annual dividend of $0.25. Kamada's payout ratio is currently 34.21%.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company's portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada's principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.